Navigation Links
Exalenz Bioscience Expands Market Coverage for the BreathID Breath Test System

Agreement with Leading Manufacturers Representative Firm Brings 10-minute, Non-radioactive 13C-urea Breath Testing to the Western U.S. States.

Newfields, NH (PRWEB) May 27, 2010 -- Exalenz Bioscience, a medical device company specializing in the diagnosis and monitoring of gastroenterological and liver related diseases, today announced it has entered into a strategic relationship with Representations, LLC, a leading Manufacturers Representative organization, to promote the BreathID® Breath Test System and Exalenz’ full line of H. pylori diagnostic solutions.

The BreathID® System is a breath test platform capable of analyzing parts-per-million changes in carbon 13 and carbon 12 ratios in a patient's breath. This system is distinguished by its ability to continuously measure breath, resulting in the fastest breath test available (10 minutes), its single-button operation for ease-of-use, and its documented superior sensitivity and specificity.

Representations has operated as a Medical Manufacturers Representative firm for 55 years. The company’s sales representatives span the thirteen western-most states and will provide focused coverage for Exalenz under the management of Exalenz’ Region Sales Managers.

“We are excited to be working with Representations,” said Dennis Boyle, Vice President and National Manager for Exalenz. “Representations has been in business for over 55 years serving and servicing the Physician’s Office market. They bring a strong history of selling capital equipment that provides unique solutions to the primary care marketplace. We look forward to a highly successful relationship with the team.”

Helicobacter pylori is a bacterium that lives in the stomach and small intestine and can cause symptoms such as bloating, and heartburn, and more severe conditions, such as gastritis, ulcers and, in some cases, gastric cancer. Conclusively eradicating H. pylori through treatment depends on an accurate diagnosis of active H. pylori infection. According to the American College of Gastroenterology’s (ACG) 2007 guidelines, the test most widely used by physicians (the Blood Antibody Test) is “no better than a coin toss in predicting active infection.” Urea Breath Testing – and the BreathID® System – have been proven to accurately and reliably detect active infection and their use is supported by the ACG clinical guidelines.

Exalenz offers physicians two distinct Urea Breath Testing solutions. The first is the Hp FasTest™, which is an in-office testing platform performed using a dedicated BreathID device that is located in the physician's office. With this option, H. pylori testing can be done on the spot with results received in around 10 minutes. The company also offers a send-in service (using the Hp BagTestTM), where collected breath samples are sent to a dedicated breath testing center for analysis.

“We believe Exalenz’ solutions for H. pylori detection have a place in every primary care physician practice,” said Ross J. Rankin, President of Representations. “There is a significant need for accurate, point-of-care testing solutions for H. pylori. We are excited to bring the BreathID® System and service to physicians in our region."

About Exalenz
Exalenz Bioscience specializes in the diagnosis and monitoring of gastroenterological and liver related diseases, using its proprietary BreathID® Breath Test platform. For additional information, please visit the company's website: and the website dedicated to the H. pylori field:

About Representations
Representations, LLC, has operated as a Medical Manufacturers Representative firm for 55 years since its founding by John Rankin. The company represents quality medical manufacturers in the medical surgical and home care fields. Headquartered in Santa Ynez, California, Representations’ sales representatives cover the thirteen western United States. For more information, please visit the company’s website:

Statements in this release of product performance, future expectations, plans and prospects may include forward looking statements. The Company's actual results, performance and execution may differ materially from those discussed, based on a variety of factors, including, among others: uncertainties with respect to market acceptance of the Company's products, risks associated with competition and competitive pricing pressures and economic conditions generally.

For more information, please call Sean Hanlon at 1-888-EXALENZ or email pr (at) exalenz (dot) com.


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Digital Pathology Services Firm Flagship Biosciences Appoints New CEO
2. Quincy Bioscience Launches; Research Studies More Accessible For Participants
3. Southridge LLC Provides Equity Capital Through Private Agreement with PuraMed Bioscience
4. Euthymics Bioscience Collaborates with GlobalSign and SafeNet to Provide an FDA Approved Electronic Signature Solution
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2009 Financial Results
6. Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services
7. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
8. Thriving Bioscience Region Leaves Its Mark
9. NYC Chiropractor Expands Practice with Therapy for Muscle and Overuse Injuries
10. Ross Group Inc Expands Sales of Membership and Customer Relationship Management Software
11. Tainted Lettuce Recall Expands
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... In an effort to ... Word of Life Christian Church of Flint, MI, hosted a family-oriented evening themed ... ton pile of candy dubbed “Candy Mountain”. , A Forever Recovery, a holistic ...
(Date:11/30/2015)... ... November 30, 2015 , ... During ... fundraising campaign to raise funds for its research, education, support, and advocacy efforts. ... organization’s annual funding. , The Mesothelioma Applied Research Foundation, which also goes by ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Catalyst continuing education course in Dallas, TX, on January 29 and 30, 2016. ... to improve the functions of their practices, to learn how to better succeed ...
(Date:11/30/2015)... ... 2015 , ... HemoTreat™ has announced that the company has ... its website. , “Our goal is simple:” says Michael Blasco, HemoTreat’s Chief Communication ... chart and ingredient list allows our customers to quickly see why, and how, ...
(Date:11/30/2015)... Scotch Plains, NJ (PRWEB) , ... November 30, ... ... is their top choice for innovative, patient centered orthopedic care. Led by ... Regardless of your injury or chronic condition, the team at Advocare Orthopedic & ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015  Hanger, Inc. (NYSE: HGR ) ... the terms of its previously announced consent solicitation (as ... $200,000,000 aggregate principal amount 7⅛% Senior Notes due 2018 ... consent fees payable pursuant to the Consent Solicitation, (ii) ... (iii) the expiration date of the Consent Solicitation.    ...
(Date:11/30/2015)... , Belgium , Nov. 30, 2015 ... sciences company focused on developing blood-based diagnostic tests for a ... the Company will present at the LD Micro Conference, which ... Los Angeles, CA. Attending from VolitionRx will be ... Scott Powell , Vice President of Investor Relations. ...
(Date:11/30/2015)... BOSTON , November 30, 2015 /PRNewswire/ ... potential new medicines directed at up to 10 G ... --> PFE ) to research and develop potential ... receptor (GPCR) targets across multiple therapeutic areas. --> ... discovery and development company and wholly-owned subsidiary of Sosei ...
Breaking Medicine Technology: